Contrast Induced Nephropathy - Pipeline Review, H2 2017

Publisher Name :
Date: 08-Aug-2017
No. of pages: 38
Price : Single User: US $ 2000  US $ 1700 Corporate User: US $ 6000  US $ 4800
Inquire Before Buying
This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Contrast Induced Nephropathy - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contrast Induced Nephropathy - Pipeline Review, H2 2017, provides an overview of the Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline landscape.

Contrast-induced nephropathy (CIN) is defined as the impairment of renal function (measured as either a 25%increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 µmol/L) increase in absolute SCr value after 48-72 hrs contrast administration). Symptoms include feeling more tired, poor appetite, swelling in the feet and ankles, puffiness around the eyes, or dry and itchy skin. Risk factors include age, diabetes, decreased kidney function and congestive heart failure. Treatment includes electrolyte management.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contrast Induced Nephropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

This report is available at 15% Discount for Single User License and 20% Discount for Corporate Users License till 01 September 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Contrast Induced Nephropathy - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Contrast Induced Nephropathy - Overview
Contrast Induced Nephropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Contrast Induced Nephropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Contrast Induced Nephropathy - Companies Involved in Therapeutics Development
Pharming Group NV
Contrast Induced Nephropathy - Drug Profiles
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-190 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize PACAP Receptors for Oncology, Cardiovascular and Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Contrast Induced Nephropathy - Dormant Projects
Contrast Induced Nephropathy - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Contrast Induced Nephropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Contrast Induced Nephropathy - Pipeline by Pharming Group NV, H2 2017
Contrast Induced Nephropathy - Dormant Projects, H2 2017
Contrast Induced Nephropathy - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Contrast Induced Nephropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • United States Hemodialysis Concentrates Market Report 2017
    Published: 15-Aug-2017        Price: US 3800 Onwards        Pages: 96
    In this report, the United States Hemodialysis Concentrates market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate o......
  • Global Hemodialysis Concentrates Sales Market Report 2017
    Published: 10-Aug-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the global Hemodialysis Concentrates market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Hemodialysis Concentrates for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe......
  • Primary Hyperoxaluria - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 33
    Primary Hyperoxaluria - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline Review, H2 2017, provides an overview of the Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) pipeline landscape. Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. It results from the overproduction of a substance called ox......
  • Global Hemodialysis Concentrates Market Research Report 2017
    Published: 03-Aug-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Hemodialysis Concentrates market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Hemodialysis Concentrates in these regions, from 2012 to 2022 (forecast), covering - North America - Europe ......
  • Hyperoxaluria - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Hyperoxaluria-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Hyperoxaluria. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Hyperoxaluria by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a speci......
  • End-Stage Kidney Disease - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "End-Stage Kidney Disease-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across End-Stage Kidney Disease. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of End-Stage Kidney Disease by development stage, therapy type, route of administration and molecule type is also covered i......
  • Lupus Nephritis - Pipeline Insight, 2017
    Published: 28-Jul-2017        Price: US 1250 Onwards        Pages: 50
    DelveInsight's, "Lupus Nephritis-Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Lupus Nephritis. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Lupus Nephritis by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a......
  • Lupus Nephritis - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Lupus Nephritis -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Lupus Nephritis in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Lupus Nephritis. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Lupus Nephritis. The report contains the targeted patient populations and......
  • Lupus Nephritis - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 28-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Lupus Nephritis - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Lupus Nephritis for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Lupus Nephritis . It enables understanding of the hist......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs